The Food and Drug Administration recently approved Belgium-based Janssen Pharmaceuticals' drug Invokamet XR for first-line use to improve glycemic control in diabetic adults when paired with diet and exercise.
Invokamet is a once-daily drug that contains a combination of canagliflozin and metformin hydrochloride. Type 2 diabetes treatment guidelines from the American Association of Clinical Endocrinologists, the American College of Endocrinology and the American Diabetes Association recommend a dual treatment method for patients with high A1C levels. A1C is a measure of average blood glucose over the past three months, according to the report.
"Invokamet XR offers the convenience of once-daily dosing and provides physicians needed flexibility for tailoring treatment to the needs of type 2 diabetes patients, especially those with higher A1C levels," said John Anderson, MD, of the Frist Clinic in Nashville, Tenn. "[P]hysicians can prescribe the XR formulation to adults when they are first diagnosed with type 2 diabetes or as additional therapy for people whose A1C levels are not well controlled with either agent alone."
More articles on supply chain:
Ohio police race through anti-overdose drug supply
Active ingredient shortage puts Bristol-Myers Squibb cancer drug on backorder
Mylan CEO acknowledges company could have anticipated consumer concern over price hike